Ligand Pharmaceuticals (LGND) Partner GlaxoSmithKline (GSK) Receives Positive Data from Promacta PIII ENABLE1 Study
Go back to Ligand Pharmaceuticals (LGND) Partner GlaxoSmithKline (GSK) Receives Positive Data from Promacta PIII ENABLE1 Study| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 52.41 +0.45 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.96 | 52 Week High | $45.58 | |||
| Open | $51.35 | 52 Week Low | $37.82 | |||
| Day High | $52.57 | P/E | N/A | |||
| Day Low | $51.35 | EPS | $0.00 | |||
| Volume | 2,404,769 | |||||
| LIGAND PHARMA (NASDAQ: LGND) | Delayed: 286.29 -1.1 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $287.39 | 52 Week High | $139.79 | |||
| Open | $288.09 | 52 Week Low | $82.07 | |||
| Day High | $289.98 | P/E | 665.79 | |||
| Day Low | $285.21 | EPS | $0.43 | |||
| Volume | 152,535 | |||||
